Facebook
Instagram
Linkedin
Pinterest
Reddit
Twitter
Youtube
Sign in
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Put Your School on the Map
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Terms and Conditions
Password recovery
Recover your password
your email
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Put Your School on the Map
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Home
Tags
Dr Jayson Dallas
Tag: Dr Jayson Dallas
Nestlé to Acquire Aimmune Therapeutics
News Wire ~ 3rd Party Press Release
-
2020/08/31
0
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development...
News Wire ~ 3rd Party Press Release
-
2020/02/05
0
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...
News Wire ~ 3rd Party Press Release
-
2019/08/21
0
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final...
News Wire ~ 3rd Party Press Release
-
2019/07/11
0
Aimmune Announces US FDA Advisory Committee Meeting Date for AR101 for...
News Wire ~ 3rd Party Press Release
-
2019/05/16
0
European Phase 3 Trial of AR101 Peanut OIT Candidate Meets Primary...
News Wire ~ 3rd Party Press Release
-
2019/03/25
0
US FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut...
News Wire ~ 3rd Party Press Release
-
2019/03/18
0
Aimmune Submits FDA Application to Offer AR101 for the Treatment of...
News Wire ~ 3rd Party Press Release
-
2018/12/21
0
Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate
News Wire ~ 3rd Party Press Release
-
2018/12/20
0
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
News Wire ~ 3rd Party Press Release
-
2018/10/15
0